IRadimed Stock

IRadimed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of IRadimed (IRMD) as of Aug 1, 2026 is 76.43 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.61 % — a change of -16.56% (lower).

FCF Conversion

76.43 %

YoY

-16.56%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of IRadimed is 2026 76.43 % . FCF Conversion Rate (FCF/EBITDA) of IRadimed was 2025 91.61 % . It decreases by -16.56% lower compared to the previous year.
Access this data via the Eulerpool API

IRadimed Stock analysis

What does IRadimed do? IRadimed Corp is an American company specializing in the development, manufacturing, and marketing of advanced medical technology products. The company was founded in 1992 and is headquartered in Winter Springs, Florida. It was founded to meet the need for advanced and precise medical devices used in intensive care. In recent years, the company has focused on the development of components and accessory products for magnetic resonance imaging (MRI) used in radiology and oncology. IRadimed Corp is known for its innovative and technologically advanced approach to the medical technology industry. The company prioritizes research and development and collaborates closely with clinics, hospitals, and medical facilities to provide the best solutions for patient care. It has a strong distribution network that allows its products to be distributed worldwide, particularly in the United States, Europe, and Asia. The company offers a wide range of medical devices and accessory products used in radiology, oncology, and other medical fields. Its specialty lies in manufacturing components and accessories for MRI. These include MRI-compatible infusion pumps, patient monitoring devices, ventilation devices, and coil arrays designed for imaging the skull and spine, as well as breast and prostate imaging. In summary, IRadimed Corp is a leading provider of medical devices and accessories for radiology, oncology, and other specialized fields. Its focus on MRI-compatible devices and accessories, as well as its collaborative approach with medical facilities, sets it apart in the industry. The company prides itself on innovation and technological advancement, offering a wide range of products tailored to the needs of patients and medical professionals. IRadimed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IRadimed stock

FCF Conversion Rate (FCF/EBITDA) of IRadimed is 76.43 % in 2026.

Access this data via the Eulerpool API

Cash Flow — IRadimed

All Key Metrics — IRadimed